Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.

Diabetes Research and Clinical Practice
Hideaki JinnouchiTomio Jinnouchi

Abstract

We investigated the effects of the SGLT2 inhibitor luseogliflozin on blood and urinary glucose and body weight. Luseogliflozin 2.5 mg was administered once daily for 24 weeks to 30 outpatients with type 2 diabetes. Urinary glucose concentration, continuous glucose monitoring values, HbA1c, fasting glucose, and body weight were evaluated. Correlations with urinary glucose, subcutaneous/visceral fat mass, insulin, EPA/AA ratio, plasma free fatty acids, ghrelin, blood ketones, plasma 1,5-anhydro-D-glucitol were evaluated. Urinary glucose significantly increased from 11.1 ± 11.8 g at Week -4 to 84.5 ± 46.8 g at Week 24. HbA1c significantly declined from 7.88 ± 0.88% to 7.36 ± 1.13% at Week 24. Mean blood glucose significantly decreased from 149.6 ± 41.8 to 131.6 ± 31.1 mg/dL at Week 24. Subcutaneous and visceral fat mass was also significantly decreased, as were AST and ALT (P < 0.01). Blood urea nitrogen was significantly increased, and urate significantly decreased from 5.04 ± 1.07 to 4.53 ± 0.94 mg/dL. The homeostasis model assessment ratio remained significantly improved throughout the treatment period. Acyl ghrelin levels remained constant but des-acyl ghrelin increased significantly. Luseogliflozin monotherapy resulted in an ...Continue Reading

References

Feb 13, 2001·Biochemical and Biophysical Research Communications·H HosodaK Kangawa
Feb 24, 2001·Nature·M NakazatoS Matsukura
Sep 13, 2003·European Journal of Pharmacology·Ivano BedendiGiampiero Muccioli
Nov 27, 2004·Diabetes Research and Clinical Practice·Mitsuo FukushimaYutaka Seino
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jul 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tomoho NodaMasamitsu Nakazato

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.